Open AccessClinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption
Author(s) -
Dean J. Kereiakes,
Stephen G. Ellis,
D. Christopher Metzger,
Ronald Caputo,
David G. Rizik,
Paul S. Teirstein,
Marc R. Litt,
Annapoorna Kini,
Ameer Kabour,
Steven O. Marx,
Jeffrey J. Popma,
Siok Hwee Tan,
Divine Ediebah,
Charles A. Simonton,
Gregg W. Stone
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.119.042584
Subject(s) - medicine , everolimus , myocardial infarction , target lesion , hazard ratio , stent , thrombosis , percutaneous coronary intervention , surgery , drug eluting stent , lesion , cardiology , urology , confidence interval
The Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support similar to those of metallic drug-eluting stents, followed by complete resorption in ≈3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) at 1 year with BVS compared with cobalt chromium everolimus-eluting stents. Between 1 and 3 years and cumulative to 3 years, adverse event rates (particularly target vessel myocardial infarction and scaffold thrombosis) were increased after BVS. We sought to assess clinical outcomes after BVS through 5 years, including beyond the 3-year time point of complete scaffold resorption.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom